Illumina announced that it acquired Edico Genome. Edico Genome’s Dragen Bio-IT Platform uses field programmable gate array technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results. Dragen can be run on premise, in the cloud, or in a hybrid mode, and is flexible and compatible for use with multiple cloud storage solutions and analysis pipelines. Edico Genome has built a strong base of NGS customers who have incorporated Dragen as a standard part of their sequencing workflow. The Dragen platform complements Illumina’s sequencing portfolio and enables customers to benefit from reduced investment in compute infrastructure, and accelerated result times, to improve their overall efficiency and to allow greater emphasis on interpretation and reporting.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.